buprenorphine + dextromethorphan

use alternative or monitor serotonin syndrome sx, especially during initiation/titration: combo may incr. risk of serotonin syndrome (additive effects)

buprenorphine + promethazine

use alternative or monitor respiratory rate, BP; decr. buprenorphine by at least 25-50%, consider decr. promethazine dose, use lowest effective doses and shortest duration of concomitant tx: combo may incr. risk of profound CNS and respiratory depression, psychomotor impairment, seizures, severe hypotension (including orthostasis, syncope), severe constipation, paralytic ileus, urinary retention (additive effects)

buprenorphine + ivosidenib

use alternative or monitor ECG, electrolytes, withdrawal sx: combo may incr. risk of QT prolongation, cardiac arrhythmias; may decr. buprenorphine levels, efficacy (additive effects; hepatic metabolism induced)

dasatinib + ivosidenib

use alternative or consider incr. dasatinib dose; monitor ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias; may decr. dasatinib levels, efficacy (additive effects; hepatic metabolism induced)

buprenorphine + iron sucrose

monitor BP: combo may incr. risk of severe hypotension, including orthostasis, syncope (additive effects)

promethazine + ivosidenib

monitor ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

promethazine + iron sucrose

monitor BP: combo may incr. risk of hypotension (additive effects)

ivosidenib + salmeterol inhaled

monitor ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)